Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.
暂无分享,去创建一个
R Möllby | M. Schenerman | S. Langermann | J. Pinkner | S. Hultgren | S. Normark | S. Koenig | R. Möllby | J Winberg | J. Winberg | S Normark | M A Schenerman | S J Hultgren | J. Burlein | S. Palaszynski | C. G. Auguste | A. Defusco | R. Strouse | L. Guldevall | M. Söderhäll | K. Ishikawa | S Koenig | J S Pinkner | S Langermann | J E Burlein | S R Palaszynski | C G Auguste | A DeFusco | R Strouse | L Guldevall | M Söderhäll | K Ishikawa | C. Auguste | Anthony W. Defusco
[1] D. Scholes,et al. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. , 1999, JAMA.
[2] K. Jansen,et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. , 1997, The Journal of infectious diseases.
[3] E. Sokurenko,et al. Diversity of the Escherichia coli Type 1 Fimbrial Lectin , 1997, The Journal of Biological Chemistry.
[4] S. Langermann,et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. , 1997, Science.
[5] R. Möllby,et al. Evaluation of the Phene Plate generalized microplate for metabolic fingerprinting and for measuring fermentative capacity of mixed bacterial populations , 1997, Journal of applied microbiology.
[6] C. Svanborg,et al. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Hughes,et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. , 1996, The New England journal of medicine.
[8] H. Mobley,et al. Urinary tract infections : molecular pathogenesis and clinical management , 1996 .
[9] P van Hoogevest,et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. , 1995, Pharmaceutical biotechnology.
[10] M. Powell,et al. Vaccine Design , 1995, Pharmaceutical Biotechnology.
[11] T. Hooton,et al. Management of urinary tract infections in adults. , 1993, The New England journal of medicine.
[12] J. Pinkner,et al. FimC is a periplasmic PapD-like chaperone that directs assembly of type 1 pili in bacteria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[13] A. Siitonen,et al. Expression of P, type-1, and type-1C fimbriae of Escherichia coli in the urine of patients with acute urinary tract infection. , 1987, The Journal of infectious diseases.
[14] A. Schaeffer,et al. Regulation of production of type 1 pili among urinary tract isolates of Escherichia coli , 1986, Infection and Immunity.
[15] A. Schaeffer,et al. Role of type 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli , 1985, Infection and immunity.
[16] J. Winberg,et al. THE PERIURETHRAL AEROBIC FLORA IN GIRLS HIGHLY SUSCEPTIBLE TO URINARY INFECTIONS , 1976, Acta Paediatrica Scandinavica.